Video

Glaucoma 360: Drug delivery contact lens technology

Author(s):

Alex Delaney-Gesing
Conferences|GLAUCOMA 360

ICYMI: Chris Adams, CEO of Diopter Corp, discusses the company's drug delivery contact lens technology in the pipeline that works to treat ocular surface disease, during the 2020 Glaucoma 360 meeting in San Francisco, California.


ICYMI: Chris Adams, CEO of Diopter Corp, discusses the company's drug delivery contact lens technology in the pipeline that works to treat ocular surface diseases, during the 2020 Glaucoma 360 meeting in San Francisco, California.

See more Glaucoma 360 coverage here

Related Videos
Related Content
Heart Eye announces AI-driven retinal imaging system to detect biomarkers of cardiovascular health risks
February 21st 2025

Heart Eye announces AI-driven retinal imaging system to detect biomarkers of cardiovascular health risks

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

(Image credit: AdobeStock/InsideCreativeHouse)
February 19th 2025

Alcon announces US launch of Voyager direct selective laser trabeculoplasty device

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

MediPrint Ophthalmics moves forward with LL-BMT1, sustained drug delivery contact lenses for glaucoma
February 15th 2025

MediPrint Ophthalmics moves forward with LL-BMT1, sustained drug delivery contact lenses for glaucoma

(Image credit: AdobeStock/flashmovie)
February 11th 2025

Retinoblastoma care goes digital: insights from two decades of teleophthalmology

© 2025 MJH Life Sciences

All rights reserved.